Development
DexCom, Inc.
DXCM
$82.26
$1.642.03%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.03B | 975.00M | 871.30M | 741.50M | 815.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.03B | 975.00M | 871.30M | 741.50M | 815.20M |
| Cost of Revenue | 377.90M | 351.70M | 324.90M | 278.90M | 273.90M |
| Gross Profit | 656.60M | 623.30M | 546.40M | 462.60M | 541.30M |
| SG&A Expenses | 308.80M | 284.70M | 297.30M | 294.60M | 305.30M |
| Depreciation & Amortization | -5.20M | 1.70M | 1.70M | 1.80M | -5.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 817.60M | 769.50M | 743.20M | 694.30M | 689.80M |
| Operating Income | 216.90M | 205.50M | 128.10M | 47.20M | 125.40M |
| Income Before Tax | 246.20M | 240.40M | 159.30M | 64.50M | 133.20M |
| Income Tax Expenses | -10.10M | 119.70M | 43.40M | 15.90M | 41.40M |
| Earnings from Continuing Operations | 256.30M | 120.70M | 115.90M | 48.60M | 91.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 256.30M | 120.70M | 115.90M | 48.60M | 91.80M |
| EBIT | 216.90M | 205.50M | 128.10M | 47.20M | 125.40M |
| EBITDA | 269.40M | 253.70M | 171.80M | 88.80M | 161.70M |
| EPS Basic | 0.67 | 0.31 | 0.30 | 0.13 | 0.24 |
| Normalized Basic EPS | 0.40 | 0.39 | 0.26 | 0.10 | 0.22 |
| EPS Diluted | 0.62 | 0.29 | 0.28 | 0.12 | 0.22 |
| Normalized Diluted EPS | 0.37 | 0.35 | 0.23 | 0.10 | 0.20 |
| Average Basic Shares Outstanding | 384.10M | 386.60M | 386.70M | 386.70M | 386.30M |
| Average Diluted Shares Outstanding | 415.90M | 426.80M | 431.50M | 418.50M | 425.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |